-transparent.png){kind=logo}
In vitro antiviral activity of V-073 against polioviruses. 2009
M Steven Oberste, and
Deborah Moore, and
Barbara Anderson, and
Mark A Pallansch, and
Daniel C Pevear, and
Marc S Collett
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
V-073, an enterovirus capsid inhibitor, was evaluated for its spectrum of antipoliovirus activity. V-073 inhibited all 45 polioviruses tested in a virus-induced cytopathic effect protection assay, with 50% effective concentration (EC50) values ranging from 0.003 to 0.126 microM. Ninety percent of the polioviruses tested were inhibited at EC(50)s of < or = 0.076 microM (MIC90 = 32 ng/ml). V-073 is a promising antiviral candidate for the posteradication management of poliovirus incidents.
Related Publications
M Steven Oberste, and
Deborah Moore, and
Barbara Anderson, and
Mark A Pallansch, and
Daniel C Pevear, and
Marc S Collett
August 2011,
Clinical and vaccine immunology : CVI,
M Steven Oberste, and
Deborah Moore, and
Barbara Anderson, and
Mark A Pallansch, and
Daniel C Pevear, and
Marc S Collett
January 2015,
The Pediatric infectious disease journal,
M Steven Oberste, and
Deborah Moore, and
Barbara Anderson, and
Mark A Pallansch, and
Daniel C Pevear, and
Marc S Collett
December 2001,
Antiviral research,
M Steven Oberste, and
Deborah Moore, and
Barbara Anderson, and
Mark A Pallansch, and
Daniel C Pevear, and
Marc S Collett
January 2011,
Antiviral therapy,
M Steven Oberste, and
Deborah Moore, and
Barbara Anderson, and
Mark A Pallansch, and
Daniel C Pevear, and
Marc S Collett
October 1967,
Bulletin of the Calcutta School of Tropical Medicine,
M Steven Oberste, and
Deborah Moore, and
Barbara Anderson, and
Mark A Pallansch, and
Daniel C Pevear, and
Marc S Collett
June 2015,
Archives of virology,
M Steven Oberste, and
Deborah Moore, and
Barbara Anderson, and
Mark A Pallansch, and
Daniel C Pevear, and
Marc S Collett
October 2018,
Antimicrobial agents and chemotherapy,
M Steven Oberste, and
Deborah Moore, and
Barbara Anderson, and
Mark A Pallansch, and
Daniel C Pevear, and
Marc S Collett
June 2008,
Journal of chemotherapy (Florence, Italy),
M Steven Oberste, and
Deborah Moore, and
Barbara Anderson, and
Mark A Pallansch, and
Daniel C Pevear, and
Marc S Collett
November 2019,
Pathogens (Basel, Switzerland),
M Steven Oberste, and
Deborah Moore, and
Barbara Anderson, and
Mark A Pallansch, and
Daniel C Pevear, and
Marc S Collett
May 2019,
Journal of ethnopharmacology,
